BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026

Rhea-AI Summary

BioLineRx (NASDAQ/TASE: BLRX) and Hemispherian announced acceptance of an e-Poster at ESMO 2026 presenting pre-clinical data showing strong synergy between GLIX1, a TET2-activating small molecule, and PARP inhibitors in HR-proficient ovarian cancer cell lines. The presentation will be held October 23–27, 2026, in Madrid.

Market Context

Current short interest was 3.27% and classified as low, adding limited short-positioning risk contex...

Analysis

Current short interest was 3.27% and classified as low, adding limited short-positioning risk context. The announcement extends GLIX1's preclinical rationale; the ESMO presentation and eventual clinical validation remain key watch points.

Key Figures

ESMO Congress dates: October 23–27, 2026 Presentation number: 1435eP New ovarian cancer cases: approximately 21,000 +3 more

6 metrics

ESMO Congress dates October 23–27, 2026 Madrid, Spain

Presentation number 1435eP ESMO 2026 e-Poster

New ovarian cancer cases approximately 21,000 United States projected in 2026

Ovarian cancer deaths 12,450 United States projected in 2026

HR-proficient tumor share approximately 50% High-grade serous ovarian cancers

Development stage Phase 1/2a GLIX1 trial initiated in the first quarter of 2026

Historical Context

5 past events · Latest: Jul 08 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 08	Ovarian preclinical data	Positive	-4.7%	Preclinical ovarian xenograft combination data showed efficacy comparable to cisplatin.
May 27	Q1 earnings report	Negative	+6.7%	Quarterly results showed a net loss despite cash runway extending into H1 2027.
May 22	ASCO data presentation	Positive	+7.0%	Two GLIX1 abstracts covered TET2 targeting, glioblastoma activity, and PARP inhibitor synergy.
May 20	Earnings scheduling notice	Neutral	+3.8%	Company scheduled Q1 results and an 8:30 a.m. conference call.
May 19	Glioblastoma preclinical data	Positive	-5.9%	GLIX1 showed anti-tumor activity across multiple glioblastoma models, including TMZ-resistant disease.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

BLRX's recent preclinical announcements produced mixed reactions, with three positive-data events followed by declines and one followed by a gain.

Key Terms

parp inhibitors, tet2, dna damage response, cytoreductive surgery

4 terms

parp inhibitors medical

"strong synergy between GLIX1 and various PARP inhibitors in HR-proficient ovarian cancer"

PARP inhibitors are a class of cancer drugs that block an enzyme cells use to repair damaged DNA, effectively preventing cancer cells from fixing themselves and causing them to die. Investors watch them because their clinical approvals, safety profiles, patent status, and tests that identify which patients will benefit determine market size and revenue potential—much like backing a tool that only works on certain problems but can be very valuable when it does.

tet2 medical

"GLIX1, a TET2 Activator Targeting the DNA Damage Response"

TET2 is a gene that makes a protein helping control which genes are turned on or off by removing chemical “tags” on DNA, like a dimmer switch for gene activity. Mutations in TET2 can allow abnormal blood cell growth and are linked to age-related clonal hematopoiesis and certain blood cancers, so it matters to investors as a biomarker that can affect diagnostic tests, patient selection, drug targets, and the commercial prospects of therapies or testing companies.

dna damage response medical

"a TET2 Activator Targeting the DNA Damage Response"

A DNA damage response is the set of cellular systems that detect and repair breaks or errors in a cell’s genetic material; think of it as a repair crew and alarm system that keeps DNA functioning properly. It matters to investors because drugs that enhance, inhibit, or exploit these repair pathways can change a therapy’s effectiveness, safety, market potential and regulatory risk, affecting the value of biotech and pharmaceutical companies.

cytoreductive surgery medical

"Standard first-line treatment consists of cytoreductive surgery"

Surgical procedure that removes as much of a tumor or cancerous tissue as possible when complete removal is not feasible, often performed to reduce tumor burden before or alongside other treatments like chemotherapy or radiation. It matters to investors because use and outcomes of this procedure can affect clinical trial design, regulatory approval, treatment adoption, hospital costs, and market demand for related drugs, devices, and services—like clearing debris so follow-up work is more effective.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TEL AVIV, Israel and OSLO, Norway, July 20, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that an abstract featuring pre-clinical data demonstrating strong synergy between GLIX1 and various PARP inhibitors in HR-proficient ovarian cancer cell lines has been accepted as an e-Poster at the 2026 European Society for Medical Oncology Annual Congress (ESMO 2026), taking place October 23^rd to October 27^th in Madrid, Spain.

Presentation Details:

Title: GLIX1, a TET2 Activator Targeting the DNA Damage Response, Synergizes with PARP Inhibitors in Ovarian Cancer Cell Lines

Presentation #: 1435eP

Presentation type: e-Poster

Location: e-Poster Area, Hall 25

About GLIX1

GLIX1 is a first-in-class, orally administered, brain penetrating, small molecule activator of the Ten-Eleven Translocation 2 (TET2) pathway that is commonly inhibited in cancer. Activating the novel TET2 pathway by GLIX1 overwhelms the DNA repair capacity of cancer cells, resulting in apoptotic cancer cell death.

About Ovarian Cancer 

Ovarian cancer is the deadliest gynecologic malignancy in the United States, with an estimated approximately 21,000 new cases and 12,450 deaths projected in 2026. Standard first-line treatment consists of cytoreductive surgery and platinum-based chemotherapy, with PARP inhibitors used as maintenance therapy in selected patients, particularly those with BRCA-mutated or homologous recombination (HR)-deficient disease. However, PARP inhibitors are markedly less effective in patients with HR-proficient tumors, which account for approximately 50% of high-grade serous ovarian cancers and are associated with primary platinum resistance and shorter survival. This leaves a substantial and currently underserved patient population in need of new treatment strategies capable of extending the benefits of PARP inhibitors.

About Hemispherian

Hemispherian AS is a clinical-stage pharmaceutical company developing first-in-class small-molecule cancer therapies. Its lead program, GLIX1, is being advanced in partnership with BioLineRx for the treatment of glioblastoma and a broad range of solid tumors.

The company is headquartered in Oslo, Norway, and collaborates with leading academic and clinical institutions worldwide.

Learn more at www.hemispherian.com or on LinkedIn.

About BioLineRx

BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company's lead development asset is GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other solid tumors, for which a Phase 1/2a clinical trial has been initiated in the first quarter of 2026. GLIX1 is being developed under a collaboration with Hemispherian AS.

The Company's first approved product, APHEXDA® (motixafortide), is indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except Asia) and Gloria Biosciences (in Asia). BioLineRx has retained the rights to develop motixafortide in solid tumors, including metastatic pancreatic cancer (PDAC), and has a Phase 2b PDAC trial currently ongoing under a collaboration with Columbia University.

Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on LinkedIn.

Forward Looking Statement

Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," and "would," and describe opinions about future events. These include statements regarding management's expectations, beliefs and intentions regarding, among other things, GLIX1's potential to sensitize patients to PARP inhibitors as well as the potential to address the need for patients with platinum-resistance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause BioLineRx's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the clinical development, commercialization and market acceptance of GLIX1 and motixafortide including the degree and pace of market uptake of APHEXDA for the mobilization of hematopoietic stem cells for autologous transplantation in multiple myeloma patients; the initiation, timing, progress and results of BioLineRx's preclinical studies, clinical trials and other therapeutic candidate development efforts; BioLineRx's ability to advance GLIX1 and motixafortide into clinical trials or to successfully complete its preclinical studies or clinical trials; whether the clinical trial results for GLIX1 and motixafortide will be predictive of real-world results; BioLineRx's receipt of regulatory approvals for GLIX1 and motixafortide and the timing of other regulatory filings and approvals; whether access to GLIX1 and motixafortide is achieved in a commercially viable manner and whether GLIX1 and motixafortide receives adequate reimbursement from third-party payors; BioLineRx's ability to establish, manage, and maintain corporate collaborations, as well as the ability of BioLineRx's collaborators to execute on their development and commercialization plans; BioLineRx's ability to integrate new therapeutic candidates and new personnel, as well as new collaborations; the interpretation of the properties and characteristics of BioLineRx's therapeutic candidates and of the results obtained with its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx's business model and strategic plans for its business and therapeutic candidates; the scope of protection that BioLineRx's is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of BioLineRx's expenses, future revenues, capital requirements and its need for and ability to access sufficient additional financing; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive companies, technologies and BioLineRx's industry; BioLineRx's ability to maintain the listing of its ADSs on Nasdaq; statements as to the impact of the political and security situation in Israel on BioLineRx's business which may exacerbate the magnitude of the factors discussed above. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 23, 2026. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

Contacts:

For BioLineRx:
United States
Chuck Padala
LifeSci Advisors, LLC
IR@biolinerx.com

Israel
Moran Meir
LifeSci Advisors, LLC
moran@lifesciadvisors.com

For Hemispherian AS: 
Zeno Albisser, CEO
zeno@hemispherian.com

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/biolinerx-and-hemispherian-as-to-present-data-demonstrating-strong-synergy-of-glix1-with-parp-inhibitors-in-hr-proficient-ovarian-cancers-at-esmo-2026-302829471.html

SOURCE BioLineRx; Hemispherian AS

FAQ

What did BioLineRx (BLRX) announce about GLIX1 and PARP inhibitors for ESMO 2026?

BioLineRx announced that pre-clinical data on GLIX1’s synergy with PARP inhibitors in HR-proficient ovarian cancer cell lines will be presented as an e-Poster at ESMO 2026. According to BioLineRx, the abstract highlights GLIX1’s activity as a TET2 pathway activator targeting DNA damage response.

When and where will BioLineRx (BLRX) and Hemispherian present GLIX1 ovarian cancer data at ESMO 2026?

The GLIX1 ovarian cancer e-Poster will be presented at ESMO 2026 from October 23–27, 2026, in Madrid, Spain. According to BioLineRx, the presentation, number 1435eP, will appear in the e-Poster Area, Hall 25, at the European Society for Medical Oncology congress.

What is GLIX1 in the BioLineRx (BLRX) pipeline and how does it work?

GLIX1 is BioLineRx’s lead development asset, a first-in-class, orally administered, brain-penetrating small molecule targeting DNA damage response. According to BioLineRx, GLIX1 activates the TET2 pathway, overwhelming cancer cells’ DNA repair capacity and inducing apoptotic cell death in glioblastoma and other solid tumors.

How could GLIX1 and PARP inhibitor synergy impact HR-proficient ovarian cancer patients?

The pre-clinical data show GLIX1 synergizing with PARP inhibitors in HR-proficient ovarian cancer cell lines, a group less responsive to current PARP therapy. According to BioLineRx, HR-proficient tumors represent about half of high-grade serous ovarian cancers, an underserved segment needing additional treatment strategies.

What stage of clinical development has GLIX1 reached in the BioLineRx (BLRX) program?

GLIX1 has entered a Phase 1/2a clinical trial in glioblastoma and other solid tumors, initiated in the first quarter of 2026. According to BioLineRx, GLIX1 is being advanced under a collaboration with Hemispherian as a potential first-in-class DNA damage response–targeting therapy.

What other approved or late-stage products does BioLineRx (BLRX) have besides GLIX1?

BioLineRx’s first approved product is APHEXDA (motixafortide), indicated in the U.S. for stem cell mobilization in multiple myeloma. According to BioLineRx, APHEXDA is commercialized by Ayrmid globally except Asia, by Gloria Biosciences in Asia, and a Phase 2b PDAC trial with motixafortide is ongoing.

Who are BioLineRx (BLRX) and Hemispherian, and how are they collaborating on GLIX1?

BioLineRx is a clinical-stage biopharmaceutical company focused on oncology and rare diseases, while Hemispherian develops first-in-class small-molecule cancer therapies. According to both companies, GLIX1 is Hemispherian’s lead program and is being jointly advanced with BioLineRx for glioblastoma and a broad range of solid tumors.